These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 26417646)

  • 41. Is transperineal prostate biopsy more accurate than transrectal biopsy in determining final Gleason score and clinical risk category? A comparative analysis.
    Scott S; Samaratunga H; Chabert C; Breckenridge M; Gianduzzo T
    BJU Int; 2015 Oct; 116 Suppl 3():26-30. PubMed ID: 26260531
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Determining Clinically Based Factors Associated With Reclassification in the Pre-MRI Era using a Large Prospective Active Surveillance Cohort.
    Gregg JR; Davis JW; Reichard C; Wang X; Achim M; Chapin BF; Pisters L; Pettaway C; Ward JF; Choi S; Nguyen QN; Kuban D; Babaian R; Troncoso P; Madsen LT; Logothetis C; Kim J
    Urology; 2020 Apr; 138():91-97. PubMed ID: 31899230
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Intermediate and Longer-Term Outcomes From a Prospective Active-Surveillance Program for Favorable-Risk Prostate Cancer.
    Tosoian JJ; Mamawala M; Epstein JI; Landis P; Wolf S; Trock BJ; Carter HB
    J Clin Oncol; 2015 Oct; 33(30):3379-85. PubMed ID: 26324359
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Metastatic Prostate Cancer in Men Initially Treated with Active Surveillance.
    Yamamoto T; Musunuru HB; Vesprini D; Zhang L; Ghanem G; Loblaw A; Klotz L
    J Urol; 2016 May; 195(5):1409-1414. PubMed ID: 26707510
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tailoring Intensity of Active Surveillance for Low-Risk Prostate Cancer Based on Individualized Prediction of Risk Stability.
    Cooperberg MR; Zheng Y; Faino AV; Newcomb LF; Zhu K; Cowan JE; Brooks JD; Dash A; Gleave ME; Martin F; Morgan TM; Nelson PS; Thompson IM; Wagner AA; Carroll PR; Lin DW
    JAMA Oncol; 2020 Oct; 6(10):e203187. PubMed ID: 32852532
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Radical Prostatectomy Findings in Men on Active Surveillance: Variable Findings Dependent on Reason for Surgery and Entry Criteria.
    Matoso A; Hassan O; Petrozzino F; Rao BV; Carter HB; Epstein JI
    J Urol; 2015 Sep; 194(3):685-9. PubMed ID: 25725419
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The relationship between tumor volume and the number of positive cores in men undergoing multisite extended biopsy: implication for expectant management.
    Ochiai A; Troncoso P; Chen ME; Lloreta J; Babaian RJ
    J Urol; 2005 Dec; 174(6):2164-8, discussion 2168. PubMed ID: 16280756
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Biopsy core number represents one of foremost predictors of clinically significant gleason sum upgrading in patients with low-risk prostate cancer.
    Capitanio U; Karakiewicz PI; Valiquette L; Perrotte P; Jeldres C; Briganti A; Gallina A; Suardi N; Cestari A; Guazzoni G; Salonia A; Montorsi F
    Urology; 2009 May; 73(5):1087-91. PubMed ID: 19195695
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Outcomes of Scheduled vs For-Cause Biopsy Regimens for Prostate Cancer Active Surveillance.
    Al-Tartir T; Murekeyisoni C; Attwood K; Badkhshan S; Mehedint D; Safwat M; Guru K; Mohler JL; Kauffman EC
    J Urol; 2016 Oct; 196(4):1061-8. PubMed ID: 27157375
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Pathologic prostate cancer characteristics in patients eligible for active surveillance: a head-to-head comparison of contemporary protocols.
    Iremashvili V; Pelaez L; Manoharan M; Jorda M; Rosenberg DL; Soloway MS
    Eur Urol; 2012 Sep; 62(3):462-8. PubMed ID: 22445138
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Role of immediate confirmatory prostate biopsy to ensure accurate eligibility for active surveillance.
    Motamedinia P; RiChard JL; McKiernan JM; DeCastro GJ; Benson MC
    Urology; 2012 Nov; 80(5):1070-4. PubMed ID: 23107398
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A nomogram for predicting low-volume/low-grade prostate cancer: a tool in selecting patients for active surveillance.
    Nakanishi H; Wang X; Ochiai A; Trpkov K; Yilmaz A; Donnelly JB; Davis JW; Troncoso P; Babaian RJ
    Cancer; 2007 Dec; 110(11):2441-7. PubMed ID: 17932909
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Underestimation of Gleason score at prostate biopsy reflects sampling error in lower volume tumours.
    Corcoran NM; Hovens CM; Hong MK; Pedersen J; Casey RG; Connolly S; Peters J; Harewood L; Gleave ME; Goldenberg SL; Costello AJ
    BJU Int; 2012 Mar; 109(5):660-4. PubMed ID: 21895937
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Continued 5α-Reductase Inhibitor Use after Prostate Cancer Diagnosis and the Risk of Reclassification and Adverse Pathological Outcomes in the PASS.
    Kearns JT; Faino AV; Schenk JM; Newcomb LF; Brooks JD; Carroll PR; Dash A; Ellis WJ; Fabrizio M; Gleave ME; Morgan TM; Nelson PS; Thompson IM; Wagner A; Zheng Y; Lin DW
    J Urol; 2019 Jan; 201(1):106-111. PubMed ID: 30076904
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pathological findings and prostate specific antigen outcomes after radical prostatectomy in men eligible for active surveillance--does the risk of misclassification vary according to biopsy criteria?
    Ploussard G; Salomon L; Xylinas E; Allory Y; Vordos D; Hoznek A; Abbou CC; de la Taille A
    J Urol; 2010 Feb; 183(2):539-44. PubMed ID: 20006888
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Reclassification rates are higher among African American men than Caucasians on active surveillance.
    Sundi D; Faisal FA; Trock BJ; Landis PK; Feng Z; Ross AE; Carter HB; Schaeffer EM
    Urology; 2015 Jan; 85(1):155-60. PubMed ID: 25440814
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Changes in Gleason score grading on serial follow-up biopsies in prostate cancer patients undergoing active surveillance.
    Guijarro A; Hernández V; López B; Capitán C; Pérez-Fernández E; de la Peña E; de la Morena JM; Llorente C
    Actas Urol Esp; 2015 Apr; 39(3):139-43. PubMed ID: 25305107
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
    Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL
    BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria.
    Mitsuzuka K; Narita S; Koie T; Kaiho Y; Tsuchiya N; Yoneyama T; Kakoi N; Kawamura S; Tochigi T; Habuchi T; Ohyama C; Arai Y
    BJU Int; 2013 May; 111(6):914-20. PubMed ID: 23320782
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The impact of obesity on the diagnosis of prostate cancer using a modern extended biopsy scheme.
    Pruthi RS; Swords K; Schultz H; Carson CC; Wallen EM
    J Urol; 2009 Feb; 181(2):574-7; discussion 578. PubMed ID: 19084847
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.